Living better or living longer? Perceptions of patients and health care professionals in oncology

Personalizing Precision Oncology Clinical Trials in Latin America: An Expert Panel on Challenges and Opportunities

The participation of patients in precision oncology trials needs to fulfill molecular-based selection criteria. This strongly limits accrual, and as a consequence, screening successes have decreased, costs have increased, and fewer subjects are enrolled. To achieve narrowed targets, studies have been forced to be multicenter and multinational to reach a larger pool of candidates. However, this globalization faces many challenges, as, for example, in the case of precision oncology trials. These trials have a complex structure that is dependent upon a high-tech infrastructure and knowledge in a dynamic environment. Given the movement of precision clinical cancer research to regions other than Europe and the U.S., it is important to evaluate the feasibility of performing such trials in lower-middle- and low-income countries. Here we critically discuss the advantages of conducting precision oncology clinical trials in Latin America and make suggestions on how to overcome the main challenges involved. IMPLICATIONS FOR PRACTICE: Precision clinical trials in oncology are studies that require candidates to have tumors with specific molecular alterations, which are considered the target for the trial experimental therapy. Because many molecular alterations are rare, fewer patients are enrolled. This has led to trials being forced to be multicenter and multinational, including trials in Latin America. This article discusses the challenges and opportunities to conduct precision oncology trials in Latin America, aiming to help sponsors and investigators to solve complex issues that ultimately lead to more of such trials being run in the region, potentially benefiting more Latin American patients with cancer.

Limitations of workers diagnosed with cancer evaluated with Work Role Functioning Questionnaire-Br

The main subject of the current study is to look into the limitations found in individuals diagnosed with cancer, considered a public health problem, especially in developing countries where the impact of this disease is expected to account for 80% of 20 million new cases estimated worldwide by 2025. For some patients undergoing treatment, continuing to be professionally active is challenging especially considering that work fosters a purpose in life, a sense of contribution, distraction, and self-esteem, which aids in physical, cognitive, emotional, and interpersonal recovery. Within this context, the aim is to describe the limitations found in individuals with cancer, who have maintained their work activities in private service during radiotherapy treatment, through a descriptive study and a quantitative approach. The final sample of 51 participants was defined by non-probability convenience sampling, based on information from all patients admitted in that period, with a research protocol approved by the Research Ethics Committee. The assessment using the Brazilian version of the Work Role Functioning Questionnaire showed higher average work functioning indexes for social demand, with an average score of 94.33 (11.47). In turn, the worst indexes were registered in physical demand. No significant differences were observed between groups of treatment protocols in terms of WRFQ-Br scores. The work functioning assessment of workers diagnosed with cancer in radiotherapy using the WRFQ-Br showed higher scores for social demands and lower for physical demands. The preserved social performance may be linked to individual work functioning within the family, at work and, consequently, within society, given that the study included patients who maintained their work activities during the proposed treatment period, highlighting the social role of work for patients with cancer.